Pipeline and Commercial Insight: Alzheimer's Disease

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2008-03-26

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

With the AD market entering a pivotal phase, Datamonitor has conducted several scenario forecasts in order to explore the possible market outlook over the next 10 years. Several pioneering Phase III disease slowing therapies offer blockbuster potential. However, should these drugs fail Phase III trials, generic competition of current therapies will see the market value decline.


Scope

  • Overview of key marketed brands and late-stage pipeline drugs.
  • Indication-specific sales volume and value forecasts to 2017 under four different scenarios.
  • Identification of future market events that are expected to affect AD drug revenues.
  • Analysis of patient potential, unmet needs and clinical trial design in AD.


    • Report Highlights
    Datamonitor\'s base scenario reveals three blockbuster potentially disease slowing drugs in the current late-stage pipeline. Wyeth/Elan\'s bapineuzumab has potential to generate multi-billion dollar revenues, and become one of the most lucrative drugs in medicine.

    The entry of potentially disease slowing therapies will not have a significant negative impact on the sales of branded current treatments. Along with the likely use of combined disease slowing and symptomatic treatments, slowing disease progression might actually increase the therapeutic window for symptomatic drugs.

    Scenario forecasts reveal a future upper limit market value of $12.7 billion to a lower limit value of $1.9 billion across the seven major markets in 2017. The affect on forecast sales revenues of different US AD prevalence rates and the success or failure of clinical programs on each key pipeline drug is explored.


    Reasons to Purchase

  • Appreciate the lucrative potential of disease slowing AD therapies, and the impact of this class on the currently marketed symptomatic drugs.
  • Assess region- (US, Japan and 5EU) and scenario-specific sales forecasts of key late-stage pipeline drugs and marketed brands.
  • Understand unmet needs and opportunities in the AD market based on key opinion leader comments.

    • Table of Contents

    Other users found this report page using the following search terms: alzheimers bapineuzumab Aricept donepezil Razadyne galantamine Exelon patch rivastigmine Namenda memantine patent alzheimers bapineuzumab expiry 2008 alzheimer pipeline disease aricept uk

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.